Current cycle? Not sure, PDUFA date is sometime next month. With such small patient population in US, it is possible to get accelerated approval with post marketing confirmatory trial. The question is whether FDA can be persuaded on the panel's suggestion that surrogate endpoint is reasonable predictor of clinical benefit. For ultra orphan indication, the chance is there; for bigger orphan indication, I would say no.
Market Data 
Markets 
AI
